Form 4: Envista Executive Nilsson Boosts Equity Holdings

Envista Holdings Corp's President of Nobel Biocare, Stefan Nilsson, increased his beneficial ownership through new equity grants and options, while also covering tax obligations.

Summary

• Stefan Nilsson, President of Nobel Biocare and an officer of Envista Holdings Corp, reported changes in his beneficial ownership.
• On February 25, 2026, 182 shares of common stock were disposed of at $29.59 per share to satisfy tax withholding obligations related to Restricted Stock Unit (RSU) vesting.
• On the same date, Nilsson acquired 7,605 Restricted Stock Units (RSUs) at a price of $0, which will vest ratably over three years.
• He also acquired 13,845 Performance Share Units (PSUs) at $0, which will vest based on achievement of performance measures over a three-year period, with a potential payout range of 0% to 200% of the target amount.
• Additionally, 18,020 Employee Stock Options were acquired with an exercise price of $29.59, vesting ratably over three years and expiring on February 25, 2036.
• Following these transactions, Nilsson directly owns 62,364 shares of common stock, 13,845 Performance Share Units, and 18,020 Employee Stock Options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects routine executive compensation grants that align management's interests with long-term shareholder value, despite a minor disposition for tax purposes.

Positives

• Acquisition of 7,605 Restricted Stock Units (RSUs) at $0, increasing future equity stake.
• Grant of 13,845 Performance Share Units (PSUs) at $0, aligning executive incentives with company performance, with potential for up to 200% of target.
• Grant of 18,020 Employee Stock Options with an exercise price of $29.59, providing long-term incentive and potential upside.

Negatives

• Disposition of 182 shares of common stock at $29.59 to cover tax withholding obligations, representing a minor reduction in direct common stock ownership.

Risks

• The vesting of Restricted Stock Units (RSUs) and Employee Stock Options is subject to continued service, meaning the executive could forfeit unvested awards if employment ceases.
• The actual number of shares received from Performance Share Units (PSUs) is contingent on achieving identified performance measures, with a potential payout of 0% if targets are not met.

Future Outlook

The grants of Restricted Stock Units, Performance Share Units, and Employee Stock Options indicate a future-oriented compensation structure. RSUs and stock options will vest ratably over three years, subject to continued service. PSUs will vest based on performance over a three-year period, aligning executive incentives with long-term company performance.

Industry Context

StockSavvy.ai notes that executive equity grants, such as RSUs, PSUs, and stock options, are standard practice in the medical technology and dental industry for aligning management incentives with shareholder interests and promoting long-term retention. These types of compensation structures are common across publicly traded companies like Dentsply Sirona (XRAY) and Align Technology (ALGN), which also utilize similar equity-based incentives for their executives to drive performance and growth in a competitive market.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs), Performance Share Units (PSUs), and Employee Stock Options for executive compensation is a common practice in the medical device and dental industry, comparable to compensation structures at companies like Dentsply Sirona (XRAY) and Align Technology (ALGN).
• The three-year vesting schedule for RSUs and stock options is typical for executive retention and long-term incentive plans across various industries.
• Performance-based vesting for PSUs, with a 0%-200% payout range, is a standard mechanism to link executive compensation directly to company performance metrics, similar to programs seen at major healthcare companies.

Related Party Transactions

• The transactions involve an officer of Envista Holdings Corp receiving equity grants and disposing of shares for tax purposes, which are considered related party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The grants of performance-based equity (PSUs) align executive incentives with shareholder value creation. The increase in potential future ownership by a key executive could be seen positively.
• Employees: The grants are part of executive compensation, which can influence overall compensation philosophy within the company.
• Management: The grants provide significant long-term incentives and retention mechanisms for Stefan Nilsson.

Next Steps

• Restricted Stock Units (RSUs) will vest ratably on each anniversary of the grant date over three years, subject to continued service.
• Performance Share Units (PSUs) will vest based on the certification of achievement of identified performance measures over a three-year performance period.
• Employee Stock Options will vest ratably on each anniversary of the grant date over three years, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation grants and a tax-related share disposition. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grants align executive incentives with long-term performance, which is a standard positive, but not a catalyst for a "buy" or "sell" decision based solely on this filing. Therefore, a "hold" recommendation is appropriate as it maintains the current position without new compelling reasons to alter it.

Keywords

Envista Holdings Corp, NVST, Stefan Nilsson, Form 4, insider transaction, beneficial ownership, Restricted Stock Units, RSUs, Performance Share Units, PSUs, Employee Stock Options, stock grants, executive compensation, Nobel Biocare